ProMIS Neurosciences (PMN) investor relations material

Company overview and business model

• Applies a patented technology platform to develop antibody therapies and vaccines for neurodegenerative and protein-misfolding diseases, focusing on Alzheimer's, MSA, and ALS.

• Pipeline includes PMN310 (lead, targeting amyloid-beta in Alzheimer's, in Phase 1b), PMN267 (targeting TDP-43 in ALS), and PMN442 (targeting a-synuclein in synucleinopathies).

• Platform leverages protein biology, physics, and supercomputing to selectively target toxic misfolded proteins.

• Operations have been funded primarily through public and private placements of shares, warrants, and convertible debt.

Financial performance and metrics

• Raised approximately $75.5 million in gross proceeds from a private placement in January 2026.

• 6,090,075 shares sold at $10.77 each, 725,221 shares at $12.13 to affiliates/insiders, and 100,000 pre-funded warrants at $10.77 less $0.0001 exercise price.

Use of proceeds and capital allocation

• Proceeds from warrant exercises, if any, will be used to advance clinical development of PMN310, for working capital, and general corporate expenses.

• No assurance that any warrants will be exercised; company will not receive proceeds from resale of shares by selling securityholders.